Roquefort Therapeutics announced a proposed acquisition of the exclusive worldwide licence to AO-252 скачать в хорошем качестве

Roquefort Therapeutics announced a proposed acquisition of the exclusive worldwide licence to AO-252

In this interview on The Watchlist, incoming chairman Sotirios Stergiopoulos discusses the science behind AO-252, its differentiated mechanism targeting DNA damage repair and immune pathways, and its potential across multiple solid tumours including ovarian, prostate, and triple-negative breast cancer. To book a CEO interview with ADVFN through The Market Link email:matthew.collom@themarketlink.com At The Market Link, we are a strategic digital marketing and investor connectivity agency. We bridge the gap between publicly traded companies and the global investment community. While traditional firms often focus on administrative compliance or institutional outreach, we specialize in investor engagement at scale. We treat your corporate story like a high-growth brand, using data-driven strategies to reach, educate, and convert the modern self-directed investor.